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INTRODUCTION
Diabetes mellitus is a syndrome of chronic hyperglycaemia due to 
relative insulin deficiency, resistance, or both.
 It affects more than 120 million people world-wide, and it is estimated 
that it will affect 220 million by the year 2020. 
Diabetes is usually irreversible and, although patients can have a 
reasonably normal lifestyle, its late complications result in reduced life 
expectancy and major health costs. 
These include macro vascular disease, leading to an increased 
prevalence of coronary artery disease, peripheral vascular disease and 
stroke, and micro vascular damage causing diabetic retinopathy and 
nephropathy.
The worldwide prevalence of DM has risen dramatically over the past 
two decades, from an estimated 30 million cases in 1985 to 177 million 
in 2000. Based on current trends, >360 million individuals will have 
diabetes by the year 2030. 
d
Although the prevalence of both type 1 and type 2 DM is increasing 
worldwide, the prevalence of type 2 DM is rising much more rapidly 
because of increasing obesity and reduced activity levels as countries 
become more industrialised.
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Approximately 1.5 million individuals (>20 years) were newly diagnosed 
with diabetes in 2005. DM increases with ageing.
 In 2005, the prevalence of DM in the United Sates was estimated to be 
0.22% in those <20 years and 9.6% in those >20 years. In individuals 
>60 years, the prevalence of DM was 20.9%.
Type 1 diabetes is a disease resulting in insulin deficiency. In western 
countries almost all patients have the immune-mediated form of the 
disease (type 1A). Type 1 diabetes is prominent as a disease of 
childhood, reaching a peak incidence around the time of puberty, but 
can present at any age.
The Diabetes Control and Complications Trial (DCCT)1 provided 
definitive proof that reduction in chronic hyperglycemia can prevent 
many of the early complications of type 1 DM. 
m
 In DCCT1 trial individuals in the intensive diabetes management group 
achieved a substantially lower hemoglobin A1C (7.3%) than individuals 
in the conventional diabetes management group (9.1%).
The DCCT1 demonstrated that improvement of glycaemic control 
reduced non proliferative and proliferative retinopathy (47% reduction), 
microalbuminuria (39% reduction), clinical nephropathy (54% reduction), 
and  neuropathy  (60%  reduction).  Improved  glycaemic  control  also 
slowed the progression of early diabetic complications. 
CARDIOVASCULAR MORBIDITY AND MORTALITY
Cardiovascular disease is increased in individuals with type 1 or 
type 2 DM. The Framingham Heart Study revealed a marked increase in 
PAD,  CHF,  CAD,  MI,  and  sudden death  (risk  increase  from one-  to 
fivefold) in DM.
9
The increase in cardiovascular morbidity and mortality appears to 
relate to the synergism of hyperglycemia with other cardiovascular risk 
factors.
In the DCCT1, the number of cardiovascular events in patients with 
type  1  diabetes  did  not  differ  between  the  standard  and  intensively 
treated groups during the trial but were reduced at follow-up 17 years 
later.
l
EFFECTS OF DIABETES ON THE MYOCARDIUM
Both systolic and diastolic abnormalities have been demonstrated 
in patients with Diabetes without symptomatic evidence of 
cardiovascular disease. These abnormalities correlate with glycaemic 
control, duration of diabetes and evidence of retinopathy/neuropathy 
(Annonu et.al 200121).
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AIMS AND OBJECTIVES 
AIMS AND OBJECTIVES OF THE STUDY
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• To study about the echo cardio graphic findings 
in type -1 diabetic patients who are on regular 
treatment.
• To study about glycaemic control .
• To detect early cardiac changes and prevent 
complications.
12
REVIEW OF LITERATURE
R
REVIEW OF LITERATURE
Diabetes Mellitus refers to a group of common metabolic disorders 
that share the phenotype of hyperglycemia. Several distinct types of DM 
exist  and  are  caused  by  a  complex  interaction  of  genetics  and 
environmental factors.
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 History is as old as mankind. It divides into pre insulin era post 
insulin era. The word Diabetes in Greek means – “I run through Siphon”. 
The Indian name for Diabetes is Madhumeha – Honey in rain. In 16th 
century, Susrutha in the  Sanskirit book of surgery, and Charaka in the 
Sanskirit  book of  medicine have mentioned about  Diabetes.  The first 
person -Vaidys – tested the urine of diabetic patients. 
Depending  on  the  etiology  of  the  DM,  factors  contributing  to 
hyperglycemia  include  reduced  insulin  secretion,  decreased  glucose 
utilization, and increased glucose production. 
The  metabolic  dysregulation  associated  with  DM  causes 
secondary  patho  physiologic  changes  in  multiple  organ  systems  that 
impose a tremendous burden on the individual with diabetes and on the 
health care system.
h
  Insulin is the key hormone involved in the storage and controlled 
release within the body of the chemical energy available from food. It is 
coded for on chromosome 11 and synthesized in the beta-cells of the 
pancreatic islets.  .  After  secretion,  insulin enters the portal  circulation 
and is carried to the liver. 
14
  
            Blood glucose levels are closely regulated in health and rarely 
stray outside the range of 3.5-8.0 mmol/L (63-144 mg/dL), despite the 
varying demands of food, fasting and exercise.
v
CRITERIA FOR DIAGNOSING DIABETES MELLITUS
• Symptoms of  Diabetes  plus  random blood glucose 
concentration - >11.1 mmol(200 mg/dl) or
• Fasting plasma glucose- 7.0 mmol/L(126 mg/dl) or
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• Two hour plasma glucose -11.1 mmol /L(200 mg/dl) 
during an oral glucose tolerance test
(Adapted from the American Diabetes Association, 2007.)
Fasting is defined as no caloric intake for at least 8 h.
The test should be performed using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water; not 
recommended for routine clinical use.
Random is defined as without regard to time since the last meal.
R
Etiologic Classification of Diabetes Mellitus
I. Type 1 diabetes (cell destruction, usually leading to absolute insulin 
deficiency)
  A. Immune-mediated
  B. Idiopathic
II. Type 2 diabetes (may range from predominantly insulin resistance 
with relative insulin deficiency to a predominantly insulin secretory defect 
with insulin resistance)
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III. Other specific types of diabetes
  A. Genetic defects of cell function characterized by mutations in:
    1. Hepatocyte nuclear transcription factor (HNF) 4 (MODY 1)
    2. Glucokinase (MODY 2)
    3. HNF-1 (MODY 3)
    4. Insulin promoter factor-1 (IPF-1; MODY 4)
    5. HNF-1 (MODY 5)
5
    6. NeuroD1 (MODY 6)
    7. Mitochondrial DNA
    8. Subunits of ATP-sensitive potassium channel
    9. Proinsulin or insulin conversion
  B. Genetic defects in insulin action
    1. Type A insulin resistance
    2. Leprechaunism
    3. Rabson-Mendenhall syndrome
    4. Lipodystrophy syndromes
  C. Diseases of the exocrine pancreas—Pancreatitis, 
Pancreatectomy, Neoplasia, Cystic Fibrosis, Hemochromatosis, 
Fibrocalculous Pancreatopathy, Mutations In carboxyl ester lipase
17
  D.Endocrinopathies—Acromegaly, Cushing's Syndrome, 
Glucagonoma, Pheochromocytoma, Hyperthyroidism, Somatostatinoma, 
Aldosteronoma
  E. Drug- or chemical-induced—Vacor, Pentamidine, Nicotinic Acid, 
Glucocorticoids, Thyroid Hormone, Diazoxide, -Adrenergic Agonists, 
G
  F. Infections—Congenital Rubella, Cytomegalovirus, Coxsackie Virus
  G. Uncommon forms of immune-mediated diabetes—
Stiff-Person -Syndrome, Anti-Insulin receptor antibodies
  H. Other genetic syndromes sometimes associated with diabetes
—
Down's Syndrome, Klinefelter's Syndrome, Turner's Syndrome, 
Wolfram's Syndrome, Friedreich's Ataxia, Huntington's Chorea, 
Laurence-Moon-Biedl Syndrome, Myotonic Dystrophy, Porphyria, 
Prader-Willi Syndrome
IV. Gestational diabetes mellitus (GDM)
(Adapted from the American Diabetes Association, 2007.)
(
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Type 1 diabetes is a disease resulting in insulin deficiency. . Type 
1  diabetes is  prominent  as  a  disease  of  childhood,  reaching  a  peak 
incidence around the time of puberty, but can present at any age. 
 Clinical clues are: 
• considerable weight loss,
•  hyperglycaemia which fails to correct with diet and 
• OHA treatment, 
• the  presence  of  strong  or  persistent  ketonuria  at 
diagnosis, and 
• autoantibody tests indicating autoimmune disease. 
a
The  highest  rates  of  type  1  diabetes  in  the  world  are  seen  in 
Finland and other Northern European countries, with the exception of 
the  island  of  Sardinia,  which  for  unknown  reasons  has  the  second 
highest rate in the world.    
The incidence of type 1 diabetes appears to be increasing in most 
populations. In Europe the annual increase is of the order of 3-4%, and 
is most marked in children under the age of 5 years. A subtype of type 
1diabetes (type 1B) has recently been described in Japanese patients 
19
with  an  abrupt  onset,  no  autoimmune  disease  and  high  serum 
pancreatic  enzyme  concentrations  at  diagnosis.  This  has  not  been 
described in other populations. 
d
PATHOGENESIS OF TYPE-1 DIABETES MELLITUS
WHO (1995) estimated that there are 19.4 million people with type 
1 diabetes and that the number will rise to 57.2 million by 2025.
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The  Diabetes  Control  and  Complications  Trial  (DCCT-1995)1 
provided  definitive  proof  that  reduction  in  chronic  hyperglycemia  can 
prevent many of the early complications of type 1 DM. 
This  large  multicenter  clinical  trial  randomized  over  1400 
individuals with type 1 DM to either intensive or conventional diabetes 
management,  and  prospectively  evaluated  the  development  of 
retinopathy, nephropathy, and 
neuropathy.  Individuals  in  the  intensive  diabetes  management 
group received multiple administrations of insulin each day along with 
extensive educational, psychological, and medical support.
 Individuals in the intensive diabetes management group achieved 
a  substantially  lower  hemoglobin  A1C (7.3%)  than  individuals  in  the 
conventional  diabetes  management  group  (9.1%).The  DCCT 
demonstrated  that  improvement  of  glycaemic  control  reduced  non 
-proliferative  and  proliferative  retinopathy  (47%  reduction), 
microalbuminuria (39% reduction), clinical nephropathy (54% reduction), 
and  neuropathy  (60%  reduction).  Improved  glycaemic  control  also 
slowed the progression of early diabetic complications.
Individuals in the intensive diabetes management group for a mean of 
6.5 years had a 42–57% reduction in cardiovascular events [nonfatal 
myocardial infarction (MI), stroke, or death from a cardiovascular event] 
at a mean follow-up of 17 years, even though their subsequent 
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glycaemic control was the same as those in the conventional diabetes 
management group.
The benefits of an improvement in glycaemic control occurred over the 
entire range of HbA1C values suggesting that at any HbA1C level, an 
improvement in glycaemic control is beneficial. The goal of therapy is to 
achieve an HbA1C level as close to normal as possible, without 
subjecting the patient to excessive risk of hypoglycemia.
The United Kingdom Prospective Diabetes Study (UKPDS3)  studied the 
course of >5000 individuals with type 2 DM for >10 years. This study 
utilized multiple treatment regimens and monitored the effect of intensive 
glycaemic control and risk factor treatment on the development of 
diabetic complications. The (UKPDS3) demonstrated that each 
percentage point reduction in HbA1C was associated with a 35% 
reduction in micro vascular complications. 
ASSESSMENT OF LONG-TERM GLYCEMIC CONTROL
Measurement of glycated hemoglobin is the standard method for 
assessing long-term glycemic control. When plasma glucose is 
consistently elevated, there is an increase in nonenzymatic glycation of 
hemoglobin; this alteration reflects the glycemic history over the previous 
2–3 months, since erythrocytes have an average life span of 120 days 
(glycemic level in the preceding month contributes about 50% to the 
A1C value). 
A
There are numerous laboratory methods for measuring the various 
forms of glycated hemoglobin, and these have significant interassay 
variations. Since glycated hemoglobin measurements are usually 
compared to prior measurements, it is essential for the assay results to 
be comparable. Depending on the assay methodology, 
hemoglobinopathies, anemias, reticulocytosis, transfusions, and uremia 
may interfere with the A1C result. Measurement of A1C at the "point of 
22
care" allows for more rapid feedback and may therefore assist in 
adjustment of therapy.
Glycated hemoglobin or A1C should be measured in all individuals with 
DM during their initial evaluation and as part of their diabetes care. 
As the primary predictor of long-term complications of DM, the A1C 
should mirror, to a certain extent, the short-term measurements of 
SMBG. These two measurements are complementary in that recent 
intercurrent illnesses may impact the SMBG measurements but not the 
A1C. Likewise, postprandial and nocturnal hyperglycemia may not be 
detected by the SMBG of fasting and preprandial capillary plasma 
glucose but will be reflected in the A1C. 
g
In standardized assays, the A1C approximates the following mean 
plasma glucose values:
an A1C of 6% is 7.5 mmol/L (135 mg/dL),
 7% is 9.5 mmol/L (170 mg/dL), 
8% is 11.5 mmol/L (205 mg/dL), etc.
 [A 1% rise in the A1C translates into a 2.0-mmol/L (35 mg/dL) increase 
in the mean glucose.]
 In patients achieving their glycemic goal, the ADA recommends 
measurement of the A1C at least twice per year. 
More frequent testing (every 3 months) is warranted when glycemic 
control is inadequate, when therapy has changed, or in most patients 
with type 1 DM. The degree of glycation of other proteins, such as 
albumin, can be used as an alternative indicator of glycemic control 
when the A1C is inaccurate (hemolytic anemia, hemoglobinopathies). 
The fructosamine assay (measuring glycated albumin) reflects the 
glycemic status over the prior 2 weeks. Alternative assays of glycemic 
control (including the 1,5 anhydroglucitol assay) should not be routinely 
used since studies demonstrating that it accurately predicts the 
complications of DM are lacking.
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2CARDIOVASCULAR MORBIDITY AND MORTALITY
Cardiovascular disease is increased in individuals with type 1 or type 2 
DM. The Framingham Heart Study revealed a marked increase in PAD, 
CHF, CAD, MI, and sudden death (risk increase from one- to fivefold) in 
DM. 
The American Heart Association has designated DM as a major risk 
factor for cardiovascular disease (same category as smoking, 
hypertension, and hyperlipidemia). The absence of chest pain ("silent 
ischemia") is common in individuals with diabetes, and a thorough 
cardiac evaluation is indicated in individuals undergoing major surgical 
procedures.
 The prognosis for individuals with diabetes who have CAD or MI is 
worse than for non diabetics. CAD is more likely to involve multiple 
vessels in individuals with DM.
In addition to CAD, cerebro vascular disease is increased in individuals 
with DM (threefold increase in stroke). Individuals with DM have an 
increased incidence of CHF. 
i
The etiology of this abnormality is probably multi factorial and includes 
factors such as myocardial ischemia from atherosclerosis, hypertension, 
and myocardial cell dysfunction secondary to chronic hyperglycemia.
a
THE MECHANISM RESPONSIBLE FOR THE DEVELOPMENT OF 
HEART FAILURE IN DIABETES.
Risk factors for CHF are common in patients with Diabetes
Direct effect of diabetes on the myocardium.
Diabetes may activate the neuro hormonal system.
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2EFFECTS OF DIABETES ON THE MYOCARDIUM
Both systolic and diastolic abnormalities have been demonstrated 
in patients with Diabetes without symptomatic evidence of 
cardiovascular disease. These abnormalities correlate with duration of 
diabetes and evidence of retinopathy/neuropathy (Annonu et.al 2001) 21.
.
ADVANCED GLYCOSYLATION END PRODUCTS (AGEs)- 
in hyperglycaemia , glucose reacts non enzymaticaly with proteins 
producing AGEs (Jyothirmayi et al., 1998)33.The AGEs are  thought to be 
involved in a number of detrimental biochemical processes
REACTIVE OXIDATIVE SPECIES –
 Prolonged hyperglycaemia causes increased oxidative stress and leads 
to increase in apoptosis in failing human heart ( Frustaci et al., 2000) 28
(SERCA 2a)
Sarcoplasmic / endoplasmic reticulum Ca2+-ATPase 2a SERCA2a 
replenishes intracellular calcium stores and is thought to play a 
important role in cardiac relaxation. AGE s cause post translational 
modification of SERCA 2a and result decreased in activity
PROTEIN KINASE  C – 
Increased activation of the signal transduction pathway for protein 
kinase C (Way et al 200138), elevated levels of protein kinase C activity 
is found in failing heart (bowling et al., 199928). Over expression of 
protein kinase c activity leads to myocardial hypertrophy and 
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dysfunction  .Elevation of protein kinase C activity is found in response 
to hyperglycaemia in cultured endothelium(way et al.,200138).Increase 
protein kinase c activity leads to an increased in extra cellular matrix 
deposition causing thickening of basement membrane ,altered colour 
flow and increases vascular permeability ,(Zhang et.al 2003)
VASCULAR ENDOTHELIAL GROWTH FACTOR-(VEGF)-
 VEGF is expressed in response to hypoxia and may play an important 
role in vascular injury. Following myocardial infarction VEGF m RNA is 
increased in arteriolar smooth muscle cells and infiltrating macrophages 
around infarct size.(shinohara et al 1996) 36.In diabetes there is a 
reduction in the amount of VEGF and its receptor found in the 
myocardium in comparison to patients without diabetes.(chou et al ., 
2002) 27.This  is consistent with pathological report  of decreased 
collateralisation in diabetic myocardium following ischemia.(Abaci et 
al.,1999) 40
 
In the myocardium, prolonged hyperglycaemia has shown the increase 
gene expression of muscle carnitine palmitoyl transferase-1(zhang et al., 
2002) 39.
This is a mitochondrial enzyme involved in the transportation of FFA s 
into the mitochondria, promoting the myocardial use of FFAs.
PATHOLOGICAL EFFECTS IN THE HEART AND THE BLOOD 
VESSELS
ENDMYOCARDIAL DYSFUNCTION
Endmyocardial dysfunction is a feature of both diabetes and CHF. In 
patients with diabetes and insulin resistant individual endothelial function 
is grossly impaired (steinbreg et al .,1999) 37. Hyper glycaemic has been 
shown to impair production of endothelium derived Nitric oxide 
(tesfamarian et al ., 1991) 41 .
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Hyperglycaemia also stimulates extra cellular matrix production  , 
thickening of the basement membrane in cultured endothelial cells 
(cagliero et al 1991) 42. 
.
Both hyperglycaemia have shown to increase production of reactive 
oxygen species by culture endothelial cells (Inoguchi et al -, 2000) 43. 
The AGE s is involved in the deactivation of nitric oxide and they impair 
vaso dilation.
ARTERIAL STIFFNESS 
Diabetes increases arterial stiffness in humans. Pulse pressure is a 
marker of arteriolar stiffness and predicts cardiovascular risk in patients 
with diabetes. Stiff arteries alter the haemodyanamics state in such a 
way that after load is increased and coronary perfusion pressure is 
decreased. It had been suggested that resultant myocardial ischemia, if 
chronic, could lead to myocardial fibrosis and impaired systolic function.
CARDIAC AUTONOMIC NEUROPATHY
Patients with autonomic neuropathy have an impaired coronary 
vasodilator response to sympathetic stimulation .Diabetic micro 
angiopathic vascular disease has been suggested as a potential 
contributor to myocardial dysfunction in patients with diabetes. 
c
LEFT VENTRICULAR FUNCTION IN DIABETES MELLITUS
Since the original description by Rubler et al based on their study from 
four adult diabetic subjects with non coronary cardiac failure and 
subsequent observation by the Framingham workers about the most 
frequent occurrence of CCF among the diabetics than could explained 
by the hypertension or ischemic heart disease alone. 
Pathological evidence among the nine diabetic subjects without 
significant atherosclerosis on post mortem examination by Regan et al 
about the presence of Periodic Acid Schiff positive material, presumably 
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a glyco protein the interstitium of the myocardium lent further support to 
existence of a specific type of heart muscle disease among diabetics.
Since the original description by Rubler et al based on their study from 
four adult diabetic subjects with non-coronary congestive cardiac failure 
(CCF) and subsequent observations by the Framingham workers about 
the most frequent occurrence of CCF among the diabetics than could be 
explained by hypertension or ischemic heart disease alone, interest was 
renewed in the field of cardiac involvement in long-standing diabetic 
patients. 
p
Impaired left ventricular (LV) function may frequently be detected in 
asymptomatic diabetic subjects and is related to the extent of diabetes 
and evidence of micro vascular complications. Although systolic and 
diastolic functions of the heart are impaired in diabetes, many studies 
have shown that the LV diastolic abnormalities are most common and 
may in fact precede the development, of systolic abnormality.
EVALUATION OF LV FUNCTION IN DIABETIC SUBJECTS
 There are two chief methods of evaluating the LV function 
• Utilizing the non-invasive techniques.
• Invasive techniques
Non-invasive methods include the assessment by
a) Systolic time intervals (STI)
b) Apex cardio graphy (ACG)
c) Radio nucleotide ventriculography
d) Echocardiography and cardiac Doppler
28
 Invasive method is by cardiac catheterization delineating the 
coronary artery anatomy and LV angiography. This procedure is 
usually reserved for  symptomatic  diabetic subjects with  overt  or 
those  who  manifest  CCF  and  is  unnecessary  in  asymptomatic 
although long-standing diabetics.
LV DIASTOLIC FUNCTION
It is now clear from the various studies that the primary functional 
abnormality in a diabetic heart is the impairment of LV diastolic function 
reflecting the reduced LV filling and that even the systolic functional 
alteration is the result of reduced LV filling. 
Diastolic function can be detected by echocardiographic technique in a 
significant number of diabetics with longer duration of both Type 1 and 2 
Diabetes mellitus patients with or without overt cardiac disease or other 
micro vascular complications.
m
M-MODE AND 2-D ECHOCARDIOGRAPHY
Aerakisnen et al utilizing the digitalized M-mode technique studied 36 
female IDDM patients with a mean duration of diabetes of 10 years or 
more and found that the most common abnormality (19 pts) was 
prolonged rapid filling period while the systolic function was normal in all. 
Another study recorded simultaneous echo and phonocardiogram in142 
diabetics. The LV relaxation, the rate and duration of cavity dimension 
increase and wall thinning were determined. Delayed mitral valve 
opening (MVO) relative to minimal LV cavity dimension and aortic valve 
closure (AVC) was found in all but 12 subjects, especially in those with 
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micro vascular complications. Prolongation of isovolumic relaxation time 
(IVRT) i.e. measured as period between AVC and MVO (abnormal, if 
more than 110 m sec), which can be demonstrated using dual M-mode 
echo preferably at 100 min/sec speed showing simultaneous aortic and 
mitral valve levels, is an important diastolic abnormality, as found by 
Sanderson et al . 
S
Others using quantitative cross-sectional echocardiography and stress 
myocardial perfusion scintigraphy found that diabetic subjects had mildly 
reduced LV end diastolic volumes and impaired diastolic filling as 
assessed by lower left atrial emptying index compared to controls .The 
left atrial emptying index is defined on M-mode tracing of the aorta.
DOPPLER TECHNIQUES 
Pulsed  Doppler  ultrasound  interrogation  of  mitral  inflow 
velocities (Doppler cursor placed at the tips of the mitral leaflets on 
apical 4-chamber view) gives a simple and reproducible method of 
determining the LV filling that correlates well with radio nucleotide 
and invasive techniques.
Ventricular filling in the normal subjects is characterized by a 
biphasic  pattern  with  an  initial  peak  velocity  of  rapid  early 
ventricular  filling  ('E')  and  a  relatively  low peak  velocity  of  late 
inflow due to atrial contraction (A). 
Impaired diastolic filling of the left ventricle in both Type 1 
and  Type  2  asymptomatic  diabetics  without  the  evidence  of 
cardiovascular 
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disease and unrelated to microangiopathic complications has 
been demonstrated using PW Doppler which showed reduction in 
the  early  filling  velocity  (reduced  'E'  peak)  and  compensatory 
increase in the late flow (increased 'A' peak) and thus increased A/
E ratio 
(i.e. A/E more than 1). 
Besides,  the  deceleration  of  'E'  velocity  is  prolonged 
indicating a slow rapid-filling phase ('E' deceleration more than 250 
m/sec). Increased atrial contribution to LV filling can be assessed 
by the area under the late diastolic filling envelope compared to 
the total diastolic area. Various studies have demonstrated these 
above  Doppler  findings  in  young  diabetic  subjects  without 
evidence of heart failure.
 A 3-year  follow-up study by Charella  et  al  of  a  group of 
asymptomatic  diabetics  with  slow  filling  and  wall  thinning 
demonstrable on echocardiography showed 31%      developing 
heart failure and 19% that died. 
Measurement of LV diastolic function may therefore prove to 
be a 
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useful  indicator  of  cardiovascular  morbidity  and  mortality  in 
diabetics. 
Hence, 
Abnormal  diastolic  function  suggestive  of  reduced LV 
compliance resulting in a 'Stiff' myocardium appears to be the 
hall  mark  of  the  specific  type  of  diabetic  heart  muscle 
disease.  The  presence  or  addition  of  hypertension  or 
coronary artery disease will certainly put a new burden on the 
already  'non-compliant’  myocardium  in  long-standing 
diabetics with or with out micro vascular complications.
PROGNOSIS 
The prognosis of left ventricular dysfunction is influenced by 
1) Degree of glycaemic control
2) Extent of ventricular fibrosis and diffuse ischemia
Tight  glycaemic  control  relatively  delays  the  dysfunction  as  the 
damage by the ischemia is irreversible and it relatively carries a 
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good prognosis. Further studies are required to determine whether 
the other agents are able to influence the myocardial function.
t
TREATMENT 
It  is unlikely that the drugs and dietary measures are less likely 
influence the development of the microangiopathy. Coronary artery has 
no role in LV dysfunction in the absence of angina due to CAD.
Two methods are currently available to modify the micro angiopathy
1) Tight control of blood sugar levels by continuous subcutaneous 
insulin infusion (CSI) has been shown to halt  or occasionally 
revert the microangiopathy.
2) Alteration  of  haemorrheology  with  Aspirin,  Dipyridamole, 
Ticlopedine,  &  Sulphinpyrosone  may  influence  micro 
angiopathy.
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But that the effect of tight control of blood sugar may improve the LV 
function  is  still  not  proven,  it  could  delay  the  progress  of  LV 
dysfunction.
With the aforesaid introduction of Diabetic Cardiomyopathy our study 
results are comparable with that of previous authors.
MATERIALS AND 
METHODS
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3MATERIALS AND METHODS
The Clinical materials were of Type-1 Diabetes Mellitus individuals 
selected from Diabetic out patient department in the AGM government 
hospital,Trichirappalli .
About 87 patients were subjected to initial assessment it included 
through  clinical  examination,  routine  blood  investigation  consisting  of 
complete blood count,  biochemistry investigation, ECG , estimation of 
HbA1c and echo cardiography were done from which 50 patients were 
included in the study.
Patients with following criteria are excluded from the study
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•  Patients with abnormal resting ECG suggestive of ischemic 
heart disease or bundle branch block etc.
• Presence  of  co  morbid  disease  known  to  influence  Left 
ventricular dysfunction:-    Thyroid disease, Alcoholism and 
Hypertension.
• Evidence of heart disease and clinical heart disease patient,
• Peripheral vascular disease,
• Cigarette smoking.
• Dyslipidemia 
D
Only  patients  who  were  in  sinus  rhythm,  free  from  signs  and 
symptoms  congestive  cardiac  failure,  Hypertension,  Anemia, 
Ischemic heart disease were included for this study.
Place of study: 
ANNAL  GANDHI  MEMORIAL  GOVERNMENT  HOSPITAL, 
TIRUCHIRAPPALLI
K.A.P.V.GOVERMENT MEDICAL COLLEGE, TIRUCHIRAPPALLI
Total number of patients – 50(Selected from the list of 87)
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They were divided into two groups according to the Glycaemic status 
one group consisted of HbA1C levels < 7, and
 the other group consisted of HbA1C levels > 7.
The number patients included in to each group was 25.
All  of  them  were  subjected  to  echo  cardiography  done  at  the 
Department of Cardiology, AGMGH, Tiruchirappalli.
Echocardiography was performed in the post absorptive phase.
E
ALOKA 830 equipment which has the capabilities of  performing 
two  dimensional,  M  mode,  Pulsed  wave  and  continuous  wave 
Doppler and colour flow imaging was used to obtain echo cardiogram 
images.
Phased array transducers 2.5 - 3.5 MHz frequencies were used to 
obtain 2-D / M-mode echo cardiography. Images were obtained with 
subjects in 30 degree lateral  decubitus position.  All  measurements 
were  performed in  the freezed images from all  the  patients,  good 
quality  images  suitable  for  the  measurements  and  interpretations 
were obtained and recorded.
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For assessment of LV systolic function the following parameters were 
calculated from the M- mode echocardiogram obtained at the level of 
mitral valve chordae.
LV  dimension  (minor  axis)  diastole  (LVId)  systole  (LVsd)  and 
thickness  of  inter  ventricular  septum,  left  ventricular  posterior  wall 
thickness in diastole.
LV ejection fraction was calculated using the following formula,
EF= LVEDV-LDESV/ LVEDV x 100
E
Specific attention was focused on diastolic function namely 
1. Calculation of left ventricular inflow velocities(e), 
2. Peak atrial contraction in Systole(a)
3. Calculation of a/e ratio and
4. Deceleration time 
5. Iso volumic relaxation time.
I
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DATA ANALYSIS
The  mean  and  standard  deviation  of  the  all  the  parameters  was 
analyzed using following formula.
INDEPENDENT T – TEST
Formula                                          x1     -  x2
s2(1/n1+1/n2)
x1 –  mean of sample -1
 x2  _  mean of sample -2
n1 – Number of subjects in sample-1 
n2 – Number of subjects in sample-2
              x12-x12/n1 +x22-x2/n1
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n1+n2 -2
The patients divided into two groups according to their HbA1c level 
as taking cutoff value as 7. The echo parameter of the two groups are 
analysed using the independent t-test and the P-value got from the t-
test table.
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OBSERVATION AND 
RESULTS
OBSERVATION AND RESULTS
The Basic characteristic of two groups well and poorly controlled Type 1 
diabetes mellitus.
Table No 1.
SL 
No Description  HB A1C <7  HB A1C >7
  Mean SD Mean SD
1 Age 22.7 5.6 30.4 6.76
2 Sex M-13,F-12 M-20,F-5
3 Duration 7.6 4.5 17.5 6.93
4 BMI 20.5 2.5 21.9 2.99
5 Hb 10.0 1.1 10.0 1.39
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6 Urea 25.8 4.6 31.2 6.26
7 S.creatinine 0.6 0.2 0.7 0.2
8 HBA1C 5.88 0.688 8.73 0.9
DISCUSSION
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4DISCUSSION
In  this  study,  we  found  a  higher  prevalence  of  asymptomatic 
diastolic  dysfunction  in  type  1  diabetes  mellitus,  in  the  absence  of 
hypertension and cardiac disease. 
These  results  support  the  concept  of  a  specific  Subclinical 
Diabetic Cardiomyopathy, which may be related to glycaemic control. 
 It showed that children and adolescents with type 1diabetes had 
altered cardiac function compared with age-matched individuals without 
diabetes. 
Subjects included in the study had no cardiac signs or symptoms 
or diabetes complications, and were not  taking medications known to 
modify cardiac structure or function.
 The most striking findings were recorded in patients with type 1 
diabetes,  who  had  reduced  diastolic  function  compared  with  control 
subjects. 
Prolonged isovolumic relaxation time reflects the rate of active left 
ventricular diastolic relaxation between aortic valve closure and opening 
of  the  mitral  valve.  Relaxation  of  the  myocardium  is  an  energy 
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dependent process requiring calcium sequestration from the cytosol into 
the sarcoplasmic reticulum, and it is altered in diabetes. 
t
Interestingly, recent magnetic resonance studies have correlated 
changes  in  myocardial  high-energy  phosphates  and  parameters  of 
diastolic function in patients with type 2 diabetes.
 Experimental  studies  have  also  shown  abnormalities  in  the 
calcium pump activity in diabetic animals (diamante et al (2003)11.
In this study, we found high Trans mitral A/E ratio as an evidence 
of reduced diastolic function, left ventricular chamber compliance, and 
changes  in  the  left  atrial  pressure.  In  the  presence  of  mild  diastolic 
dysfunction,  early  filling  is  often  reduced,  leading  to  an  exaggerated 
atrial contribution to left ventricular filling and a high A/E ratio. 
In more advanced heart failure, this pattern is often lost due to high 
left  atrial  and  left  ventricular  pressure  and  the  A/E  ratio  pseudo-
normalizes or increases, complicating interpretation (Garcia et al (1998) 
6.
Prior  studies  have  shown  a  correlation  between  HbA1c  and 
diastolic function in older individuals with  type 1 diabetes,  suggesting 
that  glycaemic  control  maybe  an  important  determinant  of  diastolic 
function - Shishehbor  (2003)(12).
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Hyperglycemia  influences  heart  metabolism,  the  production  of 
advanced  glycosylation  end  products,  oxidative  stress,  and  protein 
kinase C activation -Young et al (2003)13,, young et al (2005)14  .
1
 The relation between glycaemic control and diastolic indexes in 
study supports the hypothesis that hyperglycemia by itself can lead to 
Subclinical Cardiomyopathy.
 Results  indicate  that  diabetic  patients  with  worse  glycaemic 
control are at an increased risk of early diastolic dysfunction. 
Therefore,  in  our  study,  patients  with  type  1  diabetes  had 
increased  isovolumic  relaxation  time,  and  a  increased  A/E  ratio 
compared with normal volunteers. 
These results  are  consistent  with  prior  studies  in  asymptomatic 
normotensive  type  1  and  2  diabetic  patients  (Young  LH  (2004)14, 
Zabalgoitia  M  (2001)15  ,  Liu  JE(2001)16;  Shivalkar  (2005  ) 17  Grand 
(2006)18
Also, diastolic dysfunction was   closely related to the duration of 
diabetes.
Further study is needed to determine whether
• Intensification of  glycaemic control  improves diastolic 
parameters
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• Drugs  that  could  interfere  cellular  level  in  cardiac 
metabolism 
• Is diastolic dysfunction reversible ,if so, the time limit
SUMMARY
46
4SUMMARY
Left ventricular diastolic dysfunction is a core feature of diabetic  
heart disease.
 The aim of this prospective study was to evaluate the relation of  
hemoglobin  A1c  and  diastolic  function  in  type  1diabetes  mellitus.we 
examined echocardiographic studies of 25 patients with type 1 diabetes 
without clinical evidence of heart disease  and hemoglobin A1C<7  and 
25  patients  with  type  1  diabetes  without  clinical  evidence  of  heart  
disease  and hemoglobin A1C>7  .
In patients with type 1 diabetes without clinical evidence of heart  
disease and HbA1c >7, there was a diastolic dysfunction with higher 
trans mitral A/E ratio (0.6±0.1 vs 0.9±0.19 p<0.001), more prolonged 
isovolumic  relaxation  time  (68±7.3  vs  84±) in  comparison  with 
patients with type 1 diabetes without clinical evidence of heart disease 
and hemoglobin A1C<7 subjects. 
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4Furthermore, HbA1c correlated with diastolic Doppler indices. 
These results demonstrate that 
1. Asymptomatic  diastolic  dysfunction  is  common in  patients 
with  type 1 diabetes mellitus  and can be picked up early  
before the clinical manifestation,
2. Severity  of  the  diastolic  dysfunction  correlates  with  the 
glycaemic control,
3. Theoretical reversibility of these early cardiac changes with 
drugs can prevent progress in the clinical heart failure.
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EVALUATION OF DIASTOLIC DYSFUNCTION IN ASYMPTAMATIC 
TYPE-1 DIABETIC PATIENTS AND CORRELATES WITH HBA1C LEVELS.
NAME AGE SEX
REG NO ADDRESS
TYPE OF DIABETES- TYPE-1
DURATION
INJ INSULIN
INJ INSULIN +OAD
OTHER CO MORBID CONDITION
HYPER TENSION TB  ASTHMA OTHERS
PERSONAL HISTORY
DIET ADDICTION
SMOKER ALCOHOLISM
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FAMILY HISTORY
HYPER TENSION DM CAD COPD
AFFECTED PERSON
FATHER MOTHER SISTER BROTHER
OTHERS
CLINICAL EXAMINATION
HEIGHT WEIGHT BMI
GENERAL EXAMINATION PR BP
SYSTEMIC EXAMINATION
CVS
RS
P/A
CNS
INVESTIGATIONS
CBC
RBC
WBC
P- L- M- E-
PLATELETS
PCV
HB
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5BLOOD SUGAR
FASTING
2HR PP
HBA1C
B.UREA
S.CREATININE
URINE ROUTINE
ALBUMIN SUGAR DEPOSITS
ECHO
BASELINE ECHO CHARACTERS
1) LEFT ATRIAL AREA(cm2)
2) LV MASS INDEX (gm2)
3) LV EJECTION FRACTION(%)
4) POSTERIOR LV DIAMETER(cm)
5) IVS WALL THICKNESS
6) LV END DIASTOLIC DIAMETER
DOPPLER INDICES
1) LV PEAK EJECTION TRANS MITRAL FLOW VELOCITY-(E)-cm/s
2) PEAK ATRIAL CONTRACTION-(A)-cm/s
3) E/A- RATIO
4) DECELERATION TIME
5) ISO VOLUMIC RE3LAXATION TIME(ms)
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